U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H34N4O5S
Molecular Weight 490.616
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLIMEPIRIDE, CIS-

SMILES

CCC1=C(C)CN(C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)N[C@@H]3CC[C@H](C)CC3)C1=O

InChI

InChIKey=WIGIZIANZCJQQY-UWUNEBHHSA-N
InChI=1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19+

HIDE SMILES / InChI

Molecular Formula C24H34N4O5S
Molecular Weight 490.616
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
Haemodynamic and metabolic effects of low daily dose sulphonylureas in diabetic dog hearts.
2002
Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbits.
2002 Aug
[Molecular mechanisms of insulin secretion].
2002 Dec
Sulfonylurea stimulation of insulin secretion.
2002 Dec
Efficacy of glimepiride for the treatment of diabetes occurring during glucocorticoid therapy.
2002 Dec
Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide.
2002 Dec
Antiaggregatory activity of hypoglycaemic sulphonylureas.
2002 Jul
Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients.
2002 Jul
Effect of metabolic inhibition on glimepiride block of native and cloned cardiac sarcolemmal K(ATP) channels.
2002 Jul
Glimepiride--well tolerated in daily practice.
2002 Jul-Aug
Oral hypoglycemic sulfonylurea glimepiride preserves the myoprotective effects of ischemic preconditioning.
2002 Jun 15
Cholesterol depletion blocks redistribution of lipid raft components and insulin-mimetic signaling by glimepiride and phosphoinositolglycans in rat adipocytes.
2002 Mar
Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes.
2002 Nov
Immunoreactive insulin response to a single dose of glimepiride in lean type 2 diabetic subjects.
2002 Oct
Dynamics of plasma membrane microdomains and cross-talk to the insulin signalling cascade.
2002 Oct 30
Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
2002 Sep
[Glimepiride in daily practice].
2003
[A 50-year history of new drugs in Japan-the development and progress of anti-diabetic drugs and the epidemiological aspects of diabetes mellitus].
2003
A flaw in the use of sulfonylurea screening to diagnose sulfonylurea overdosages.
2003
Inadvertent sulfonylurea overdosage and hypoglycemia in an elderly woman: failure of serum hypoglycemia screening.
2003
[Glimepiride--an oral antidiabetic agent].
2003
Glimepiride treatment and IGF-I in adolescents with type 1 diabetes: a prospective, randomized, double-blind, placebo-controlled study.
2003 Apr
Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone.
2003 Aug
Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al.
2003 Dec
Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in Type 2 diabetes: a multicentre retrospective cohort study.
2003 Dec
Effects of glimepiride on HbA(1c) and body weight in Type 2 diabetes: results of a 1.5-year follow-up study.
2003 Jul
Effect of glimepiride on serum adiponectin level in subjects with type 2 diabetes.
2003 Jul
Glimepiride reduces mononuclear activation of the redox-sensitive transcription factor nuclear factor-kappa B.
2003 Jul
Lispro insulin and metformin versus other combination in the diabetes mellitus type 2 management after secondary oral antidiabetic drug failure.
2003 Jun
Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.
2003 Jun
Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.
2003 Jun
Glimepiride in type 2 diabetes mellitus: a review of the worldwide therapeutic experience.
2003 Mar
The mechanisms underlying the unique pharmacodynamics of nateglinide.
2003 Mar
[Differences between oral antidiabetics].
2003 Mar 20
Combined bedtime insulin--daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate--a randomised trial.
2003 Mar-Apr
Effects of sulfonylureas on K(ATP) channel-dependent vasodilation.
2003 Mar-Apr
Pitfalls in endosonographic imaging of suspected insulinomas: pancreatic nodules of unknown dignity.
2003 May
Study of glimepiride-b-cyclodextrin complex.
2003 Nov
Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiride.
2003 Nov
The influence of glimepiride on the oxidative state of rats with streptozotocin-induced hyperglycemia.
2003 Nov
Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.
2003 Nov
Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
2003 Nov-Dec
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes.
2003 Oct
Glimepiride pharmacokinetics in obese versus non-obese diabetic patients.
2004 Jan
Protective actions of gliclazide on high insulin-enhanced neutrophil-endothelial cell interactions through inhibition of mitogen activated protein kinase and protein kinase C pathways.
2004 Jan
The influence of glimepiride on the binding kinetics of insulin with its skeletal muscle and liver receptors in rats with short term and prolonged hyperglycemia induced by streptozotocin.
2004 Jan
Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity.
2004 Jan
Long-acting sulfonylureas -- long-acting hypoglycaemia.
2004 Jan 19
Determination of glimepiride in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry.
2004 Jan 5
Prevention of weight gain in type 2 diabetes requiring insulin treatment.
2004 Mar
Patents
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:00:55 GMT 2023
Edited
by admin
on Sat Dec 16 08:00:55 GMT 2023
Record UNII
24T6XIR2MZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLIMEPIRIDE, CIS-
Common Name English
1-((4-(2-(((3-ETHYL-4-METHYL-2-OXO-2,3-DIHYDRO-1H-PYRROL-1-YL)CARBONYL)AMINO)ETHYL)PHENYL)SULFONYL)-3-(CIS-4-METHYLCYCLOHEXYL)UREA
Systematic Name English
GLIMEPIRIDE CIS-ISOMER
Common Name English
GLIMEPIRIDE IMPURITY A [EP IMPURITY]
Common Name English
GLIMEPIRIDE RELATED COMPOUND A [USP IMPURITY]
Common Name English
GLIMEPIRIDE RELATED COMPOUND A
USP  
Common Name English
1H-PYRROLE-1-CARBOXAMIDE, 3-ETHYL-2,5-DIHYDRO-4-METHYL-N-(2-(4-(((((CIS-4-METHYLCYCLOHEXYL)AMINO)CARBONYL)AMINO)SULFONYL)PHENYL)ETHYL)-2-OXO-
Systematic Name English
GLIMEPIRIDE RELATED COMPOUND A [USP-RS]
Common Name English
Code System Code Type Description
CAS
684286-46-2
Created by admin on Sat Dec 16 08:00:55 GMT 2023 , Edited by admin on Sat Dec 16 08:00:55 GMT 2023
PRIMARY
RS_ITEM_NUM
1292314
Created by admin on Sat Dec 16 08:00:55 GMT 2023 , Edited by admin on Sat Dec 16 08:00:55 GMT 2023
PRIMARY
FDA UNII
24T6XIR2MZ
Created by admin on Sat Dec 16 08:00:55 GMT 2023 , Edited by admin on Sat Dec 16 08:00:55 GMT 2023
PRIMARY
PUBCHEM
3476
Created by admin on Sat Dec 16 08:00:55 GMT 2023 , Edited by admin on Sat Dec 16 08:00:55 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP